One target-multiple indications: a call for an integrated common mechanisms strategy

Area of Science:

• Drug discovery and development
• Pharmaceutical industry innovation
• Therapeutic target evaluation

Background:

• Rising research and development costs pressure the pharmaceutical industry.
• Current methods for maximizing drug value, like life-cycle management, are often initiated late in the process.
• Developing follow-up drugs from validated targets can enhance safety or convenience.

Purpose of the Study:

• To introduce and advocate for a systematic 'common mechanism' approach.
• To evaluate the full therapeutic potential of drug targets, lead structures, or candidates early in development.
• To improve efficiency and output in the pharmaceutical research pipeline.

Main Methods:

• Systematic evaluation of therapeutic potential.
• Early-stage assessment of drug targets, lead structures, and drug candidates.
• Application of the 'common mechanism' strategy.

Main Results:

• The 'common mechanism' approach enables broader and earlier evaluation of therapeutic potential.
• This systematic strategy aims to enhance pharmaceutical R&D efficiency.
• Potential for improved drug development outcomes through early, comprehensive assessment.

Conclusions:

• The 'common mechanism' approach offers a novel strategy for pharmaceutical R&D.
• Early and broad evaluation of therapeutic potential can mitigate risks and costs.
• This method facilitates maximizing the value of drug assets throughout their lifecycle.